Abstract
Acinetobacter baumannii (A. baumannii) is an important opportunistic pathogen widely present in medical environment. Given its complex drug resistance, A. baumannii poses a serious threat to the safety of critically ill patients. Given the limited alternative antibiotics, nonantibiotic-based functional anti-A. baumannii infection proteins must be developed. In this study, we firstly used a series of biological software to predict potential epitopes in the MacB protein sequence and verified them by antibody recognition and lymphocyte proliferation tests. We finally screened out B cell epitope 2, CD8+ T cell epitope 7, and CD4+ T cell epitope 11 and connected them to construct a recombinant antigen epitope (RAE). The determination of IgG in the serum of immunised mice and cytokines in the supernatant of lymphocytes showed that the constructed epitope induced an immune response mediated by Th-1 cells. Finally, the challenge experiment of A. baumannii infection in mice confirmed that the epitope developed based on MacB, especially RAE, provided incomplete immune protection for mice.
Highlights
Acinetobacter baumannii (A. baumannii, Ab) is an important opportunistic pathogen in clinical environment [1].The bacterium is widely distributed in hospital environments and can survive for a long time in specific departments, such as intensive care units [2], neurosurgery [3], and respiratory medicine [4], causing infection in critically ill patients
Horseradish peroxidaselabelled secondary antibody was added. 3,3 ′,5,5 ′ -Tetramethylbenzidine was used for colour reaction, and optical density (OD) value was measured at 450 nm by microplating after the reaction was stopped by H2SO4
A. baumannii can show strong resistance to various kinds of antibiotics commonly used in the clinic
Summary
The bacterium is widely distributed in hospital environments and can survive for a long time in specific departments, such as intensive care units [2], neurosurgery [3], and respiratory medicine [4], causing infection in critically ill patients. The drug resistance of A. baumannii has become a global challenge [11]; CR-Ab tops the World Health Organization’s list of pathogens in need of new antibiotics [12]. In the presence of CRAb, when clinicians use high-level antibiotics, such as tetracycline and polymyxin, the treatment effect is occasionally unsatisfactory [13]. This condition causes heavy financial burden to patients and harmful drug side effects caused
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
